Repligen (NASDAQ:RGEN) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations

What happened

Repligen reported Q3 2026 revenue of $209.3 million, up 10.9% year on year and ahead of analyst estimates. Adjusted profit was $0.53 per share, beating estimates by 14.6%, and the company raised full-year revenue guidance to $848 million at the midpoint.

Confirmed

Global impact / market context

Higher revenue and profit than analysts expected suggest demand for Repligen's biopharma manufacturing products is holding up. The raised full-year revenue outlook signals management expects continued sales growth, which can support the share price and fund future capital spending.

Analyst inference

Repligen's operating margin fell to -14.1% from 8.9% a year earlier, and free cash flow margin dropped to 18.1% from 23%, so profit quality weakened even as sales grew. Investors may weigh strong revenue against these cost and cash pressures.

Analyst inference

What to watch

1. Watch whether Repligen delivers the $848 million midpoint full-year revenue guidance and $2.07 adjusted profit per share guidance it raised this quarter. Confirmed
2. Management could face questions on why operating margin turned negative at -14.1% and free cash flow margin fell, which may shape investor confidence in future profits. Proposed
3. If organic revenue growth of 12.5% continues, Repligen may need more capital spending and staff, affecting costs, cash available and profit per sale in coming quarters. Analyst inference

Evidence

• stockstory.org